Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD.

Banerjee A, Koziol-White C, Panettieri R Jr.

Curr Opin Pharmacol. 2012 Jun;12(3):287-92. doi: 10.1016/j.coph.2012.01.016. Epub 2012 Feb 24. Review.

2.

Tristetraprolin and its role in regulation of airway inflammation.

Prabhala P, Ammit AJ.

Mol Pharmacol. 2015 Apr;87(4):629-38. doi: 10.1124/mol.114.095984. Epub 2014 Nov 26. Review.

3.

Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease.

Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, Stoelben E, Strauch J, Koch A.

J Pharmacol Exp Ther. 2010 Dec;335(3):788-98. doi: 10.1124/jpet.110.166843. Epub 2010 Aug 26.

4.

Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.

Terajima M, Inoue T, Magari K, Yamazaki H, Higashi Y, Mizuhara H.

Eur J Pharmacol. 2013 Jan 5;698(1-3):455-62. doi: 10.1016/j.ejphar.2012.11.021. Epub 2012 Nov 23.

PMID:
23183108
5.

Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.

Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, Haddad el-B, Barnes PJ, Newton R.

Mol Pharmacol. 2006 Aug;70(2):697-705. Epub 2006 May 10.

6.

Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.

Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D.

J Pharmacol Exp Ther. 2011 Sep;338(3):732-40. doi: 10.1124/jpet.111.180737. Epub 2011 May 24.

7.

Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.

Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK.

Int J Chron Obstruct Pulmon Dis. 2015 Feb 4;10:283-91. doi: 10.2147/COPD.S72403. eCollection 2015.

8.

Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone.

Raidl M, Sibbing B, Strauch J, Müller K, Nemat A, Schneider PM, Hag H, Erdmann E, Koch A.

Cell Biochem Biophys. 2007;49(2):98-110.

PMID:
17906365
10.

Progress towards the development of anti-inflammatory inhibitors of IKKbeta.

Bamborough P, Callahan JF, Christopher JA, Kerns JK, Liddle J, Miller DD, Morse MA, Rumsey WL, Williamson R.

Curr Top Med Chem. 2009;9(7):623-39. Review.

PMID:
19689370
11.

A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients.

Singh D, Smyth L, Borrill Z, Sweeney L, Tal-Singer R.

J Clin Pharmacol. 2010 Jan;50(1):94-100. doi: 10.1177/0091270009347873. Epub 2009 Oct 30.

PMID:
19880675
12.

Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy.

Johansen C, Vinter H, Soegaard-Madsen L, Olsen LR, Steiniche T, Iversen L, Kragballe K.

Br J Dermatol. 2010 Dec;163(6):1194-204. doi: 10.1111/j.1365-2133.2010.10036.x.

PMID:
20846304
13.

Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases.

Chopra P, Kanoje V, Semwal A, Ray A.

Expert Opin Investig Drugs. 2008 Oct;17(10):1411-25. doi: 10.1517/13543784.17.10.1411 . Review.

PMID:
18808304
14.

Kinase inhibitors and airway inflammation.

Adcock IM, Chung KF, Caramori G, Ito K.

Eur J Pharmacol. 2006 Mar 8;533(1-3):118-32. Epub 2006 Feb 8. Review. Retraction in: Eur J Pharmacol. 2012 May 15;683(1-3):340.

PMID:
16469308
15.

Frontrunners in novel pharmacotherapy of COPD.

Barnes PJ.

Curr Opin Pharmacol. 2008 Jun;8(3):300-7. doi: 10.1016/j.coph.2008.03.001. Epub 2008 May 3. Review.

PMID:
18457992
16.

Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IkappaB kinase inhibitors.

Newton R, Holden NS, Catley MC, Oyelusi W, Leigh R, Proud D, Barnes PJ.

J Pharmacol Exp Ther. 2007 May;321(2):734-42. Epub 2007 Feb 22.

17.
18.

DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.

Kang JS, Kim HM, Choi IY, Han SB, Yoon YD, Lee H, Park KH, Cho IJ, Lee CW, Lee K, Lee KH, Park SK.

J Pharmacol Exp Ther. 2010 Aug;334(2):657-64. doi: 10.1124/jpet.109.161687. Epub 2010 Apr 28.

19.

New therapies for chronic obstructive pulmonary disease.

Barnes PJ.

Med Princ Pract. 2010;19(5):330-8. doi: 10.1159/000316368. Epub 2010 Jul 14. Review.

20.

Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.

Grund EM, Kagan D, Tran CA, Zeitvogel A, Starzinski-Powitz A, Nataraja S, Palmer SS.

Mol Pharmacol. 2008 May;73(5):1394-404. doi: 10.1124/mol.107.042176. Epub 2008 Feb 5.

Supplemental Content

Support Center